RecruitingPhase 3NCT06303739

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study


Sponsor

University of North Carolina, Chapel Hill

Enrollment

23 participants

Start Date

Apr 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: * Does psilocybin with assisted therapy help improve symptoms for people with depression? * How long do the effects of this treatment last? Participants will: * Take part in a couple of screening and preparation visits. * Be given psilocybin in one or two treatment sessions. * Attend a series of follow-up sessions over the following year. * Complete forms and surveys to test how their symptoms have changed and what they thought of their experience. Researchers will also compare whether one treatment or two treatments help improve symptoms more for participants.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study tests psilocybin-assisted therapy — a single or small number of guided psychedelic sessions using psilocybin (the active compound in 'magic mushrooms') — as a treatment for people with severe depression that has not responded to at least two different antidepressant medications. Therapy sessions are led by trained guides. **You may be eligible if...** - You are an adult with a confirmed diagnosis of major depressive disorder - You are currently in a depressive episode lasting at least 3 months - You have tried at least 2 antidepressant medications from different drug classes without adequate relief - You are in generally good health based on medical history and basic lab tests - You have no significant cognitive impairment - You have a support person who can accompany you home after sessions **You may NOT be eligible if...** - You have a history of psychosis, schizophrenia, or bipolar disorder type I - You have serious heart, liver, or seizure conditions - You are currently taking medications that interact with psilocybin (such as lithium or certain antidepressants) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGpsilocybin

25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.


Locations(1)

UNC Chapel Hill Medical Center

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06303739


Related Trials